Fig. 3
From: EpCAM as multi-tumour target for near-infrared fluorescence guided surgery
EpCAM specificity and intra-operative tumor-to-background ratios (TBR’s): Competition with 1 mg of cold 323/A3 antibody significantly decreased the percentage of injected dose 323/A3-800CW per gram tumor (%ID/g) indicating in vivo tumor specificity a. After development of subcutaneous HT29-luc2 tumors, 1 nmol (150ug) of 323/A3-800CW, MOPC21-800CW and IRDye 800CW was injected intravenously. TBR’s were calculated from 4 h to 120 h after injection b. Subsequently, 1 nmol (150ug) 323/A3-800CW and MOPC21-800CW was intravenously injected in mice bearing orthotopic colon (HT29-luc2), breast (MCF-7-luc2-cGFP) and tongue (OSC-19-luc2-cGFP) tumors c. TBR’s were calculated 72 h post injection. TBR’s of EpCAM specific antibody 323/A3-800CW in colon, breast and head & neck cancer are significantly higher compared to those of the control antibody MOPC21-800CW